Abstract: The invention relates to the combined administration of a PDE4 or PDE3/4 inhibitor and a disease modifying anti-rheumatic drug (DMARDs) or anti-rheumatic or anti-arthritic drug.
Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.
Abstract: Compounds of a certain formula I in which R1, R2, R3 and R4 have the meanings indicated in the description are novel compounds expected to be useful in the therapy of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis.
Type:
Application
Filed:
September 5, 2005
Publication date:
November 1, 2007
Applicant:
Altana Pharma AG
Inventors:
Thomas Maier, Armin Zuelch, Thomas Ciossek, Thomas Baer, Thomas Beckers
Abstract: The invention provides compounds of the formula 1, in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
Abstract: The invention relates to compounds of the formula (1) in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.
Abstract: Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel, effective compounds with anti-proliferative and/or apoptosis inducing activity.
Type:
Application
Filed:
May 25, 2005
Publication date:
October 18, 2007
Applicant:
Altana Pharma AG
Inventors:
Klaus Pekari, Thomas Baer, Bjorn Bartels, Mathias Schmidt, Thomas Beckers
Abstract: Compounds of the formula (1) in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.
Type:
Application
Filed:
August 17, 2005
Publication date:
October 4, 2007
Applicant:
Altana Pharma AG
Inventors:
Matthias Vennemann, Thomas Baer, Gudrun Groegor, Jurgen Braunger, Petra Gimmnich, Thomas Maier, Heike Rothfels
Abstract: The invention relates to a novel process for preparing mixtures of enantiomers of PPI's having a sulphinyl structure using a mixture of enantiomers of chiral zirconium complexes or chiral hafnium complexes.
Type:
Application
Filed:
May 31, 2005
Publication date:
September 27, 2007
Applicant:
Altana Pharma AG
Inventors:
Bernhard Kohl, Bernd Mueller, Ralf Weingart
Abstract: Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective PDE 3/4 inhibitors.
Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.
Abstract: The invention provides compounds of the formula I in which the substitutents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.
Abstract: The invention relates to compounds of the formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds are valuable intermediates for the preparation of pharmaceutical active compounds.
Abstract: The invention relates to pharmaceutical formulations containing combinations of ciclesonide and a pharmaceutically acceptable salt of glycopyrronium and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.
Abstract: Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective HDAC inhibitors.
Type:
Application
Filed:
March 10, 2005
Publication date:
August 9, 2007
Applicant:
ALTANA PHARMA AG
Inventors:
Thomas Maier, Thomas Beckers, Thomas Baer, Petra Gimmnich, Frank Dullweber, Matthias Vennemann
Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.